Archive for December 2017
Chugai Commits $220M Into Singapore Drug Lab
The drugmaker intends to expand development of therapeutic antibodies at the lab. Source: BioSpace
Read MoreJohnson & Johnson's Potential Depression Blockbuster Esketamine Shows Promise in Phase II Study
The drug showed a significant, clinically meaningful and fast-acting improvement in depression symptoms compared to an intranasal placebo. Source: BioSpace
Read MoreWhy Investors Should Dodge Gilead in 2018
Thanks to the Republican tax legislation, pharmaceutical stocks are set to continue their heady northward trajectory in 2018. Source: BioSpace
Read MoreInvestors Irate as J.P. Morgan Bars Press From Biggest Biotech Conference of the Year
The J.P. Morgan Healthcare Conference is held every year in early January, and this year it will be Jan. 8-11 in San Francisco, as usual. Source: BioSpace
Read MoreCelgene Takes a $411M Hit From Discontinuation of Crohn's Disease Trials
Celgene announced back in October that it was discontinuing its GED-0301 program for Crohn’s disease and now that decision is costing the company $411M. Source: BioSpace
Read MoreThe Numbers Are In: Bay Area's Depomed Reveals 328 Job Cuts in WARN Notice
The company’s sales department will take the brunt of the layoffs, losing 235 jobs. Source: BioSpace
Read MoreShanghai's SARI Pays $359M for Italian Cancer Biopharma NMS
The parts expect the closing in the first quarter 2018. Source: BioSpace
Read More4 Biotechs Ready to Kill the Market in 2018
A look at a few biotechs which should outperform the market in 2018: Source: BioSpace
Read MoreAstraZeneca Unloads Four NDAs to ANI Pharmaceuticals in $46.5M Deal
ANI Phamaceuticals funded the acquisitions through a combination of cash and debt. Source: BioSpace
Read MoreBay Area's Menlo Therapeutics Files for $98M IPO
Menlo Therapeutics filed on Thursday with the SEC to raise up to $98M in an IPO. Source: BioSpace
Read More